Promoter holding
64.27%
JP
Jubilant Pharmova Limited - Due diligence report
A 360° intelligence report on Jubilant Life Sciences: trust score, financial health, credit view, compliance, directors, growth and distress…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Jubilant Life Sciences — 360° Intelligence Report
Generated from MCA filings & public records72/100
Trust Score
Moderate
Jubilant Life Sciences is assessed as Moderate with a Trust Score of 72/100. Jubilant Life Sciences is an active public limited indian non-government company incorporated in 1978, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 25 Jul 2026 from the latest processed filings. Jubilant Pharmova Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
72/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
42/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
70/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
80/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 70/100 Moderate
- Profitable - internal accruals available.
- Externally credit-rated (AA).
Charges position: 5 open (360.00 cr) · 79 satisfied (9,185.57 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 9 | 48.0 cr |
| Housing Development Finance Corporation Limited | 3 | 48.0 cr |
| Axis Bank Limited | 3 | 48.0 cr |
| State Bank Of India | 4 | 48.0 cr |
| Corporation Bank Industrial Finance Branch | 3 | 48.0 cr |
| Central Bank Of India | 2 | 48.0 cr |
Compliance Score: 42/100 Caution Indicated
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: DSE, CLB, SEBI.
- Litigation present in 5 court forum(s).
- Delayed payments to MSME suppliers disclosed (918 disclosure(s)).
- 4 active GST registration(s).
Legal cases on record (5)
05
Director Intelligence
Stability score: 80/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ARVIND CHOKHANY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHYAM SUNDER BHARTIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HARI SHANKER BHARTIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARUN KUMAR SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHIVPRIYA NANDA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHIRISH GUNDOPANT BELAPURE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARUN SETH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUSHIL KUMAR ROONGTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NARESH KAPOOR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HARSH MAHAJAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARVIND CHOKHANY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARJUN SHANKER BHARTIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NARESH KAPOOR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIVEK MEHRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PRIYAVRAT BHARTIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 15 directors on the board.
- No disqualified or deactivated DINs.
- 4 director exits in 3 years - high churn.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
6
Group entities
6
Capital events
7 allotment(s) · 0 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Jubilant Biosys Limited | Subsidiary Company | 74.00% |
| Jubilant Business Services Limited | Subsidiary Company | 74.00% |
| Jubilant Cadista Pharmaceutials Inc | Subsidiary Company | 74.00% |
| Jubilant Clinsys Inc. | Subsidiary Company | 74.00% |
| Jubilant Clinsys Limited | Subsidiary Company | 74.00% |
| Jubilant Discovery Services Llc | Subsidiary Company | 74.00% |
| Jubilant Draximage (usa) Inc. | Subsidiary Company | 74.00% |
| Jubilant Draximage Inc. | Subsidiary Company | 74.00% |
| Jubilant Draximage Radiopharmacies Inc. | Subsidiary Company | 74.00% |
| Jubilant Epicore Llc | Subsidiary Company | 74.00% |
Key managerial personnel: ARVIND CHOKHANY (Whole-time director) · ARUN KUMAR SHARMA (CFO) · ARVIND CHOKHANY (CFO) · ARJUN SHANKER BHARTIA (Managing Director) · PRIYAVRAT BHARTIA (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 85 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +38% over 4 year(s).
Profit expanded 1.42 year-on-year.
Asset base grew 2.1x - capacity expansion.
Net margin improved to 24%.
EPFO headcount growing - hiring signal.
Operating for 48+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (42/100).
5 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 17.77 cr.
5 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence65/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment64/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 5 open charge(s) of 360.00 cr already registered.
- Compliance gaps should be priced into terms.
Investor view78/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 5 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events14 Nov 2025
Charge satisfied
Axis Bank Limited
28 Oct 2025
Charge satisfied
Others
01 Oct 2025
Director appointed
ARUN KUMAR SHARMA (CFO)
29 Aug 2025
Charge created
Others - 50.00 cr
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
25 Jun 2024
Director ceased
SHIVPRIYA NANDA
Director ceased
HARSH MAHAJAN
01 Jun 2024
Director ceased
ARUL RAMAKRISHNAN
01 Apr 2024
Director appointed
SHIVPRIYA NANDA (Director)
Director appointed
HARSH MAHAJAN (Director)
26 Feb 2024
Charge created
Hdfc Bank Limited - 100.00 cr
01 Nov 2023
Director ceased
JINANG PRATAP PAREKH
28 Aug 2023
Charge created
Others - 100.00 cr
27 Jun 2023
Director appointed
ARVIND CHOKHANY (CFO)
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
15 active director(s) / partner(s); board looks stable and experienced.
4 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 6 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of AA from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 7 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Max Estates | L70200DL2016PLC438718 | New Delhi, Delhi, India |
| Tüv Rheinland | U72501KA1996PTC020653 | Bangalore, Karnataka, India |
| Rec Pdcl | U40101DL2007GOI165779 | New Delhi, Delhi, India |
| Sojitz India Private Limited | U51909DL2005PTC134445 | New Delhi, Delhi, India |
| Reward360 | U74900KA2012PTC067399 | Bengaluru, Karnataka, India |
| Ciel Hr | U74140TN2010PLC077095 | Chennai, Tamil Nadu, India |
| Dalmia Bharat Limited | L40109TN2006PLC058818 | Thiruuchirapalli Dt, Tamil Nadu, India |
| Central Mine Planning & Design Institute | L14292JH1975GOI001223 | Jharkhand, Jharkhand, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Jubilant Life Sciences before audits and certifications: compliance score 42/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Jubilant Life Sciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 70/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Jubilant Life Sciences - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 72/100, distress signals and MSME payment-delay disclosures - know whether Jubilant Life Sciences pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (5 case(s) on record), regulatory flags, charge documents trail and director networks for Jubilant Life Sciences - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Jubilant Life Sciences an active company?
Jubilant Life Sciences has MCA status “Active” with a compliance score of 42/100 (Caution Indicated).
Is Jubilant Life Sciences financially healthy?
Jubilant Life Sciences has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.
Should I do business with Jubilant Life Sciences?
Its overall Trust Score is 72/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Jubilant Life Sciences?
Promoters hold a minority stake - exact percentages are in the full report. 15 active director(s) are on record.
Does Jubilant Life Sciences have loans or charges against its assets?
5 open charge(s) are registered against its assets, and 79 earlier charge(s) stand satisfied.
Is Jubilant Life Sciences up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 42/100 (Caution Indicated).
Is it risky to lend to Jubilant Life Sciences?
Its Credit Risk Score is 70/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
